


Biosimilars Market To Grow At Rate Of 27% With Increasing Prevalence Of Chronic Diseases

The Business Research Company's Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, August 3, 2021 /EINPresswire.com/ -- Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biosimilars are increasingly used to treat these chronic diseases. Biosimilars activate the immune system response against cancer cells thus helping the immune



system to eliminate the cancer cells from the body. The key players operating in the <u>biosimilars</u> <u>market</u> are investing in creating a biosimilar of insulin.

The major players covered in the global biosimilar drugs market are Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, and STADA Arzneimittel.

The global biosimilar market size 2020 was \$7.49 billion. It is expected to grow to \$8.05 billion in 2021 at a compound annual growth rate (CAGR) of 7.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilars market is expected to reach \$21.13 billion in 2025 at a CAGR of 27%, The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.

Read More On The Global Biosimilars Market Report: https://www.thebusinessresearchcompany.com/report/biosimilars-market-global-report

The biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired.

TBRC's biosimilars report is segmented by product into recombinant non-glycosylated proteins, recombinant glycosylated proteins; by types into human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, others' by application into oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, others.

<u>Biosimilars Global Market Report 2021: COVID-19 Growth And Change To 2030</u> is one of a series of new reports from The Business Research Company that provides biosimilars global market overview, forecast biosimilars global market size and growth for the whole market, biosimilars market segments, and geographies, biosimilars global market trends, biosimilars market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Biosimilars Market Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Biosimilar Therapeutic Peptides Global Market Report 2021: COVID-19 Growth And Change To 2030

(https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptides-global-market-report-2020-30-covid-19-growth-and-change)

Biosimilar Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

(https://www.thebusinessresearchcompany.com/report/biosimilar-monoclonal-antibodies-global-market-report-2020-30-covid-19-growth-and-change)

Interested to know more about <u>The Business Research Company?</u>
Read more about us at <u>https://www.thebusinessresearchcompany.com/about-the-businessresearch-company.aspx</u>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: https://bit.ly/3b7850r
Follow us on Twitter: https://bit.ly/3b1rmjS
Check out our Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:

Facebook Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/547907173

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.